Ximelagatran

Jump to: navigation, search
Ximelagatran2.png
Ximelagatran
Systematic (IUPAC) name
ethyl 2-[[(1R)-1-cyclohexyl-2-
[(2S)-2-[[4-(N'-hydroxycarbamimidoyl)
phenyl]methylcarbamoyl]azetidin-1-yl]-
2-oxo-ethyl]amino]acetate
Identifiers
CAS number 192939-46-1
ATC code B01AE05
PubChem 5478933
Chemical data
Formula C24H35N5O5 
Mol. mass 474 (429 after conversion)
Pharmacokinetic data
Bioavailability 20%
Metabolism None
Half life 3-5h
Excretion Renal (80%)
Therapeutic considerations
Pregnancy cat.

uncategorised

Legal status

Rx only/POM

Routes Oral

WikiDoc Resources for

Ximelagatran

Articles

Most recent articles on Ximelagatran

Most cited articles on Ximelagatran

Review articles on Ximelagatran

Articles on Ximelagatran in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ximelagatran

Images of Ximelagatran

Photos of Ximelagatran

Podcasts & MP3s on Ximelagatran

Videos on Ximelagatran

Evidence Based Medicine

Cochrane Collaboration on Ximelagatran

Bandolier on Ximelagatran

TRIP on Ximelagatran

Clinical Trials

Ongoing Trials on Ximelagatran at Clinical Trials.gov

Trial results on Ximelagatran

Clinical Trials on Ximelagatran at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ximelagatran

NICE Guidance on Ximelagatran

NHS PRODIGY Guidance

FDA on Ximelagatran

CDC on Ximelagatran

Books

Books on Ximelagatran

News

Ximelagatran in the news

Be alerted to news on Ximelagatran

News trends on Ximelagatran

Commentary

Blogs on Ximelagatran

Definitions

Definitions of Ximelagatran

Patient Resources / Community

Patient resources on Ximelagatran

Discussion groups on Ximelagatran

Patient Handouts on Ximelagatran

Directions to Hospitals Treating Ximelagatran

Risk calculators and risk factors for Ximelagatran

Healthcare Provider Resources

Symptoms of Ximelagatran

Causes & Risk Factors for Ximelagatran

Diagnostic studies for Ximelagatran

Treatment of Ximelagatran

Continuing Medical Education (CME)

CME Programs on Ximelagatran

International

Ximelagatran en Espanol

Ximelagatran en Francais

Business

Ximelagatran in the Marketplace

Patents on Ximelagatran

Experimental / Informatics

List of terms related to Ximelagatran

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Ximelagatran (Exanta® or Exarta®, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.

Method of action

Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. It acts solely by inhibiting the actions of thrombin. It is taken orally twice daily, and rapidly absorbed by the small intestine. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen).

Uses

Ximelagatran was expected to replace warfarin and sometimes aspirin and heparin in many therapeutic settings, including deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation such as stroke. The efficacy of ximelagatran for these indications had been well-documented (Eriksson et al 2003, Frances et al 2004, Schulman et al 2004).

An advantage, according to early reports by its manufacturer, was that it could be taken orally without any monitoring of its anticoagulant properties. This would have set it apart from warfarin and heparin, which require monitoring of the international normalized ratio (INR) and the partial thromboplastin time (PTT), respectively. A disadvantage recognised early was the absence of an antidote in case acute bleeding develops, while warfarin can be antagonised by vitamin K and heparin by protamine sulfate.

Side-effects

Ximelagatran was generally well tolerated in the trial populations, but a small proportion (5-6%) developed elevated liver enzyme levels, which prompted the FDA to reject an initial application for approval in 2004. The further development was discontinued in 2006 after it turned out hepatic damage could develop in the period subsequent to withdrawal of the drug. According to AstraZeneca, a chemically different but pharmacologically similar substance, AZD0837, is undergoing testing for similar indications (AstraZeneca press release 2006).

References


Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg
Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox
In other languages